Company registration number SC401988 (Scotland)
AQUA PHARMA TECHNICAL LTD
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
PAGES FOR FILING WITH REGISTRAR
AQUA PHARMA TECHNICAL LTD
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 6
AQUA PHARMA TECHNICAL LTD
BALANCE SHEET
AS AT
31 DECEMBER 2024
31 December 2024
- 1 -
2024
2023
Notes
£
£
£
£
Fixed assets
Tangible assets
3
13,750
26,504
Current assets
Stocks
123,712
295,926
Debtors
4
26,618
165,016
Cash at bank and in hand
26,152
9,275
176,482
470,217
Creditors: amounts falling due within one year
5
(324,261)
(578,228)
Net current liabilities
(147,779)
(108,011)
Net liabilities
(134,029)
(81,507)
Capital and reserves
Called up share capital
100
100
Profit and loss reserves
(134,129)
(81,607)
Total equity
(134,029)
(81,507)

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 26 September 2025 and are signed on its behalf by:
Elvin Bugge
Hanne Mertens
Director
Director
Company Registration No. SC401988
AQUA PHARMA TECHNICAL LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 2 -
1
Accounting policies
Company information

Aqua Pharma Technical Ltd is a private company limited by shares incorporated in Scotland. The registered office is 4th Floor Metropolitan House, 31-33 High Street, Inverness, IV1 1HT.

 

It is the intention of the directors to cease trading post year end.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention.The principal accounting policies adopted are set out below.

1.2
Going concern

Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

 

When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and equipment
33% straight line
Fixtures and fittings
33% straight line
Motor vehicles
33% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.5
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

AQUA PHARMA TECHNICAL LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 3 -
1.6
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.7
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.8
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.9
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

AQUA PHARMA TECHNICAL LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 4 -
1.10
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.11
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.12
Government grants

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

 

A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.

1.13
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
1
3
AQUA PHARMA TECHNICAL LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 5 -
3
Tangible fixed assets
Plant and equipment
Fixtures and fittings
Motor vehicles
Total
£
£
£
£
Cost
At 1 January 2024
111,584
26,726
65,198
203,508
Disposals
(27,978)
-
0
-
0
(27,978)
At 31 December 2024
83,606
26,726
65,198
175,530
Depreciation and impairment
At 1 January 2024
86,807
24,999
65,198
177,004
Depreciation charged in the year
10,169
534
-
0
10,703
Eliminated in respect of disposals
(25,927)
-
0
-
0
(25,927)
At 31 December 2024
71,049
25,533
65,198
161,780
Carrying amount
At 31 December 2024
12,557
1,193
-
0
13,750
At 31 December 2023
24,777
1,727
-
0
26,504
4
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
22,229
13,233
Other debtors
4,389
151,783
26,618
165,016
5
Creditors: amounts falling due within one year
2024
2023
£
£
Trade creditors
1,181
1,962
Amounts owed to group undertakings
80,000
56,997
Taxation and social security
3,607
-
0
Other creditors
239,473
519,269
324,261
578,228
6
Audit report information

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006:

The auditor's report was unqualified.

AQUA PHARMA TECHNICAL LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
6
Audit report information
(Continued)
- 6 -
Senior Statutory Auditor:
Paul Capewell FCA CA
Statutory Auditor:
A9 Accountancy Limited
7
Related party transactions
2024
2023
Amounts due to related parties
£
£
Entities with control, joint control or significant influence over the company
186,816
-
Other related parties
80,000
559,173

The following amounts were outstanding at the reporting end date:

2024
2023
Amounts due from related parties
£
£
Entities with control, joint control or significant influence over the company
21,066
-
Other related parties
1,162
13,233
8
Parent company

The immediate parent company is Aqua Pharma Group AS, a company registered in Norway. Its registered office is Hovemovegen 1, 2624, Lillehammer, Norway.

 

The ultimate parent company is Aquatiq AS, a company registered in Norway.

 

2024-12-312024-01-01falsefalsefalse26 September 2025CCH SoftwareCCH Accounts Production 2025.100No description of principal activityElvin BuggeHanne MertensSC4019882024-01-012024-12-31SC4019882024-12-31SC4019882023-12-31SC401988core:PlantMachinery2024-12-31SC401988core:FurnitureFittings2024-12-31SC401988core:MotorVehicles2024-12-31SC401988core:PlantMachinery2023-12-31SC401988core:FurnitureFittings2023-12-31SC401988core:MotorVehicles2023-12-31SC401988core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-31SC401988core:CurrentFinancialInstrumentscore:WithinOneYear2023-12-31SC401988core:CurrentFinancialInstruments2024-12-31SC401988core:CurrentFinancialInstruments2023-12-31SC401988core:ShareCapital2024-12-31SC401988core:ShareCapital2023-12-31SC401988core:RetainedEarningsAccumulatedLosses2024-12-31SC401988core:RetainedEarningsAccumulatedLosses2023-12-31SC401988bus:Director12024-01-012024-12-31SC401988bus:Director22024-01-012024-12-31SC401988core:PlantMachinery2024-01-012024-12-31SC401988core:FurnitureFittings2024-01-012024-12-31SC401988core:MotorVehicles2024-01-012024-12-31SC4019882023-01-012023-12-31SC401988core:PlantMachinery2023-12-31SC401988core:FurnitureFittings2023-12-31SC401988core:MotorVehicles2023-12-31SC4019882023-12-31SC401988core:WithinOneYear2024-12-31SC401988core:WithinOneYear2023-12-31SC401988core:EntitiesWithJointControlOrSignificantInfluenceOverReportingEntity2024-12-31SC401988bus:PrivateLimitedCompanyLtd2024-01-012024-12-31SC401988bus:SmallCompaniesRegimeForAccounts2024-01-012024-12-31SC401988bus:FRS1022024-01-012024-12-31SC401988bus:Audited2024-01-012024-12-31SC401988bus:FullAccounts2024-01-012024-12-31xbrli:purexbrli:sharesiso4217:GBP